NCT00609856View on ClinicalTrials.gov

Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions

Type 2 DiabetesSecondary Drug Failure

Interventions

DRUG

pioglitazone

tablet, 30 mg, once daily, 26 weeks

DRUG

insulin glargine

subcutaneous injection, start dose 6-10 units, once daily, 26 weeks

Trial Locations (1)

20502

Malmö University Hospital, Malmo

Sponsors

Collaborators (1)

Medical Research Council

All Listed Sponsors

collaborator

Medical Research Council

OTHER_GOV

collaborator

Skane County Council Research & Development Foundation

UNKNOWN

lead

Skane University Hospital

OTHER